[Gentamycin sulfate effectiveness and tolerance in patients with myelotoxic agranulocytosis].
Patients with myelotoxic agranulocytosis were treated with gentamicin administered intravenously as drop-wise infusions in a dose of 5 mg/kg body weight a day every 8 hours. The treatment course consisted of 7--24 days. No toxic reactions were observed. The therapeutic efficacy of gentamicin depended on the neutrophilic level and amounted to 50--60 per cent when the drug was used without identification of the causative agent. The prophylactic use of gentamicin decreased the infection incidence in patients with myelotoxic agranulocytosis, while the prophylactic efficacy of gentamicin was evident only when the number of the granulocytes was higher than 100/mm3 of the blood.
D000380:Agranulocytosis / Q000188:drug therapy*; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D004361:Drug Tolerance; D005069:Evaluation Studies as Topic; D005839:Gentamicins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007938:Leukemia / Q000188:drug therapy; D008223:Lymphoma / Q000188:drug therapy; D009503:Neutropenia / Q000188:drug therapy
D005839:Gentamicins
Effektivnost' i perenosimost' gentamitsina sul'fata u bol'nykh s mielotoksicheskim agranulotsitozom.